JP2023040036A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023040036A5 JP2023040036A5 JP2022203459A JP2022203459A JP2023040036A5 JP 2023040036 A5 JP2023040036 A5 JP 2023040036A5 JP 2022203459 A JP2022203459 A JP 2022203459A JP 2022203459 A JP2022203459 A JP 2022203459A JP 2023040036 A5 JP2023040036 A5 JP 2023040036A5
- Authority
- JP
- Japan
- Prior art keywords
- gastric retention
- retention system
- adamantane
- drug
- release rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002496 gastric effect Effects 0.000 claims 51
- 230000014759 maintenance of location Effects 0.000 claims 43
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims 42
- 150000003839 salts Chemical class 0.000 claims 28
- 229940079593 drug Drugs 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 22
- 229920006254 polymer film Polymers 0.000 claims 17
- 229920001610 polycaprolactone Polymers 0.000 claims 10
- 239000004632 polycaprolactone Substances 0.000 claims 10
- 239000002202 Polyethylene glycol Substances 0.000 claims 9
- 229920001223 polyethylene glycol Polymers 0.000 claims 9
- 229920000642 polymer Polymers 0.000 claims 9
- 239000012530 fluid Substances 0.000 claims 8
- -1 transition metal salts Chemical class 0.000 claims 7
- 208000012902 Nervous system disease Diseases 0.000 claims 5
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 5
- 229960004640 memantine Drugs 0.000 claims 5
- 229920001451 polypropylene glycol Polymers 0.000 claims 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 5
- 239000003361 porogen Substances 0.000 claims 5
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 4
- 229960003805 amantadine Drugs 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 230000000926 neurological effect Effects 0.000 claims 4
- 229920001515 polyalkylene glycol Polymers 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 229920002125 Sokalan® Polymers 0.000 claims 3
- 229920001400 block copolymer Polymers 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- 229920001971 elastomer Polymers 0.000 claims 3
- 239000000806 elastomer Substances 0.000 claims 3
- 239000004014 plasticizer Substances 0.000 claims 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims 3
- 239000011118 polyvinyl acetate Substances 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 210000001187 pylorus Anatomy 0.000 claims 3
- 210000002784 stomach Anatomy 0.000 claims 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- RKPSOUZGYPZAHW-UHFFFAOYSA-N adapromine Chemical compound C1C(C2)CC3CC2CC1(C(N)CC)C3 RKPSOUZGYPZAHW-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- LWJALJDRFBXHKX-UHFFFAOYSA-N bromantane Chemical compound C1=CC(Br)=CC=C1NC1C(C2)CC3CC2CC1C3 LWJALJDRFBXHKX-UHFFFAOYSA-N 0.000 claims 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229920001531 copovidone Polymers 0.000 claims 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 claims 2
- 229950004543 neramexane Drugs 0.000 claims 2
- SENUTBBWBZZNRT-LVEBTZEWSA-N nitromemantine Chemical compound C([C@](C1)(N)C2)[C@@]3(CC)C[C@]2(CC)C[C@]1(O[N+]([O-])=O)C3 SENUTBBWBZZNRT-LVEBTZEWSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 239000004584 polyacrylic acid Substances 0.000 claims 2
- 229920000570 polyether Polymers 0.000 claims 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims 2
- 229960000888 rimantadine Drugs 0.000 claims 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims 2
- 230000036962 time dependent Effects 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- UXQDWARBDDDTKG-UHFFFAOYSA-N tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 claims 2
- 229960000832 tromantadine Drugs 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 229920002148 Gellan gum Polymers 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010061285 Mental disorder due to a general medical condition Diseases 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920001100 Polydextrose Polymers 0.000 claims 1
- 229920002675 Polyoxyl Polymers 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 150000005215 alkyl ethers Chemical class 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 230000000181 anti-adherent effect Effects 0.000 claims 1
- 239000003911 antiadherent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000010692 aromatic oil Substances 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 239000000378 calcium silicate Substances 0.000 claims 1
- 229910052918 calcium silicate Inorganic materials 0.000 claims 1
- 235000012241 calcium silicate Nutrition 0.000 claims 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229960005168 croscarmellose Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 1
- 229960003280 cupric chloride Drugs 0.000 claims 1
- 150000002009 diols Chemical class 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940032296 ferric chloride Drugs 0.000 claims 1
- 229960001781 ferrous sulfate Drugs 0.000 claims 1
- 239000011790 ferrous sulphate Substances 0.000 claims 1
- 235000003891 ferrous sulphate Nutrition 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 235000010492 gellan gum Nutrition 0.000 claims 1
- 239000000216 gellan gum Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims 1
- 235000013856 polydextrose Nutrition 0.000 claims 1
- 239000001259 polydextrose Substances 0.000 claims 1
- 229940035035 polydextrose Drugs 0.000 claims 1
- 239000000622 polydioxanone Substances 0.000 claims 1
- 229920000151 polyglycol Polymers 0.000 claims 1
- 239000010695 polyglycol Substances 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 239000004323 potassium nitrate Substances 0.000 claims 1
- 235000010333 potassium nitrate Nutrition 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims 1
- 229910052939 potassium sulfate Inorganic materials 0.000 claims 1
- 235000011151 potassium sulphates Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 229920002379 silicone rubber Polymers 0.000 claims 1
- 239000004945 silicone rubber Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 235000010234 sodium benzoate Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims 1
- 229960001763 zinc sulfate Drugs 0.000 claims 1
- 229910000368 zinc sulfate Inorganic materials 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402947P | 2016-09-30 | 2016-09-30 | |
| US62/402,947 | 2016-09-30 | ||
| US201762490466P | 2017-04-26 | 2017-04-26 | |
| US62/490,466 | 2017-04-26 | ||
| US201762517718P | 2017-06-09 | 2017-06-09 | |
| US62/517,718 | 2017-06-09 | ||
| JP2019516937A JP2019532947A (ja) | 2016-09-30 | 2017-09-29 | アダマンタン系薬物の持続的送達のための胃内滞留システム |
| PCT/US2017/054608 WO2018064630A1 (en) | 2016-09-30 | 2017-09-29 | Gastric residence systems for sustained delivery of adamantane-class drugs |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516937A Division JP2019532947A (ja) | 2016-09-30 | 2017-09-29 | アダマンタン系薬物の持続的送達のための胃内滞留システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023040036A JP2023040036A (ja) | 2023-03-22 |
| JP2023040036A5 true JP2023040036A5 (enExample) | 2023-08-30 |
| JP7565999B2 JP7565999B2 (ja) | 2024-10-11 |
Family
ID=61760251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516937A Withdrawn JP2019532947A (ja) | 2016-09-30 | 2017-09-29 | アダマンタン系薬物の持続的送達のための胃内滞留システム |
| JP2022203459A Active JP7565999B2 (ja) | 2016-09-30 | 2022-12-20 | アダマンタン系薬物の持続的送達のための胃内滞留システム |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516937A Withdrawn JP2019532947A (ja) | 2016-09-30 | 2017-09-29 | アダマンタン系薬物の持続的送達のための胃内滞留システム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11576866B2 (enExample) |
| EP (1) | EP3518902A4 (enExample) |
| JP (2) | JP2019532947A (enExample) |
| CN (2) | CN118766834A (enExample) |
| AU (1) | AU2017336154B2 (enExample) |
| CA (1) | CA3038557A1 (enExample) |
| WO (1) | WO2018064630A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016016406A (es) | 2014-06-11 | 2017-10-12 | Massachusetts Inst Technology | Estructuras de permanencia, y métodos relacionados. |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| WO2016178971A1 (en) | 2015-05-01 | 2016-11-10 | Massachusetts Institute Of Technology | Triggerable shape memory induction devices |
| AU2016342374B2 (en) | 2015-10-23 | 2022-08-04 | Nortiva Bio, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
| KR102796240B1 (ko) | 2015-12-08 | 2025-04-16 | 린드라 테라퓨틱스 인코퍼레이티드 | 위 체류 시스템을 위한 기하 구성형태 |
| US12109305B2 (en) | 2016-05-27 | 2024-10-08 | Lyndra Therapeutics, Inc. | Materials architecture for gastric residence systems |
| TWI811221B (zh) | 2017-06-09 | 2023-08-11 | 美商萊恩卓治療公司 | 具有釋放速率調節膜之胃的滯留系統 |
| WO2019071087A1 (en) * | 2017-10-06 | 2019-04-11 | DigiM Solution LLC | SYSTEM AND METHOD FOR CALCULATING PERFORMANCE OF CONTROLLED RELEASE OF MEDICINE USING IMAGES |
| CA3118056A1 (en) * | 2018-08-15 | 2020-02-20 | Lyndra, Inc. | Systems for enteric delivery of therapeutic agents |
| WO2020117855A1 (en) | 2018-12-03 | 2020-06-11 | Lyndra, Inc. | Stomach simulating device |
| CN113840596A (zh) | 2019-03-20 | 2021-12-24 | 林德拉治疗公司 | 用于胃滞留剂型的衣层 |
| IL286512B2 (en) * | 2019-03-20 | 2026-03-01 | Lyndra Therapeutics Inc | Capsules and capsule coatings for stomach-retaining dosage forms |
| EP4054538A4 (en) * | 2019-11-08 | 2024-02-07 | Lyndra Therapeutics, Inc. | STOMACH RESIDENCE SYSTEMS WITH A FILAMENT FOR IMPROVED STOMACH RESIDENCE |
| WO2021092486A1 (en) * | 2019-11-08 | 2021-05-14 | Lyndra, Inc. | Formulations for release-rate modulating films for gastric residence systems |
| CA3160665A1 (en) * | 2019-11-08 | 2021-05-14 | Lyndra Therapeutics, Inc. | Gastric residence systems for administration of active agents |
| IL292848A (en) * | 2019-11-08 | 2022-07-01 | Lyndra Therapeutics Inc | Polymeric links for the gastric retention system |
| EP4121017A4 (en) * | 2020-03-17 | 2024-07-03 | Blaesi, Aron H. | EXPANDABLE, MULTI-EXCIPIENT STRUCTURED DOSAGE FORM FOR EXTENDED ACTIVE INGREDIENT RELEASE |
| CN116234540A (zh) | 2020-07-29 | 2023-06-06 | 赛康特集团有限责任公司 | 具有包括交联聚(癸二酸甘油酯)的结构的形状引导控释和滞留 |
| JP2024503485A (ja) * | 2021-01-19 | 2024-01-25 | リンドラ セラピューティクス， インコーポレイティド | リスペリドンを投与するための胃内滞留システム |
| AU2022270208A1 (en) * | 2021-05-05 | 2023-12-07 | Lyndra Therapeutics, Inc. | Gastric residence systems comprising methadone |
| EP4333823A4 (en) * | 2021-05-05 | 2025-04-09 | Lyndra Therapeutics, Inc. | Indwelling gastric sytems containing buprenorphine and naloxone |
| IL314378A (en) * | 2022-01-19 | 2024-09-01 | Lyndra Therapeutics Inc | Dosage forms for gastric preservation |
| WO2024249946A2 (en) * | 2023-06-02 | 2024-12-05 | Lyndra Therapeutics, Inc. | Manufacturing methods for gastric residence systems |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1957564A (en) | 1932-11-23 | 1934-05-08 | Aubra T West | Expanding capsule body |
| US3154461A (en) | 1960-03-07 | 1964-10-27 | Minnesota Mining & Mfg | Matte-finish polymeric film and method of forming the same |
| US3531368A (en) | 1966-01-07 | 1970-09-29 | Toray Industries | Synthetic filaments and the like |
| US3716614A (en) | 1969-05-12 | 1973-02-13 | Toray Industries | Process of manufacturing collagen fiber-like synthetic superfine filament bundles |
| AU449029B2 (en) | 1969-08-28 | 1974-04-17 | Commonwealth Scientific And Industrial Research Organisation | Device for administration to ruminants |
| JPS5512411B2 (enExample) | 1974-03-12 | 1980-04-02 | ||
| US4304767A (en) | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
| NO155805C (no) | 1981-02-06 | 1987-06-10 | Ucb Sa | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter. |
| US4451260A (en) * | 1982-03-26 | 1984-05-29 | Minnesota Mining And Manufacturing Company | Sustained release oral medicinal delivery device |
| US4676507A (en) | 1985-05-06 | 1987-06-30 | Patterson Bruce D | Puzzles forming platonic solids |
| US4735804A (en) * | 1985-05-10 | 1988-04-05 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| DE3680024D1 (de) | 1985-05-10 | 1991-08-08 | Merck & Co Inc | Abgabesystem fuer arzneimittel, das waehrend einer kontrollierten zeitspanne im magen zurueckgehalten werden kann. |
| US4758436A (en) | 1985-05-29 | 1988-07-19 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4767627A (en) * | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| EP0253554A3 (en) | 1986-07-15 | 1988-07-20 | Pfizer Inc. | Controlled release drug-containing fibers |
| CA1314742C (en) | 1986-12-12 | 1993-03-23 | Hiromu Terada | Optical fiber array |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| US5002772A (en) | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
| NZ228382A (en) | 1989-03-17 | 1992-08-26 | Carter Holt Harvey Plastic Pro | Drug administering coil-like device for insertion in body cavity of animal |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| NZ234227A (en) | 1989-06-30 | 1991-08-27 | Smithkline Beecham Corp | Delayed release dosage form |
| JPH03163011A (ja) * | 1989-08-31 | 1991-07-15 | Yamanouchi Pharmaceut Co Ltd | 胃内滞留デバイス |
| US5047464A (en) | 1989-09-20 | 1991-09-10 | Merck & Co., Inc. | Bioerodible thermoset elastomers |
| US5121329A (en) | 1989-10-30 | 1992-06-09 | Stratasys, Inc. | Apparatus and method for creating three-dimensional objects |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US5939467A (en) | 1992-06-26 | 1999-08-17 | The Procter & Gamble Company | Biodegradable polymeric compositions and products thereof |
| US5369142A (en) | 1993-01-15 | 1994-11-29 | The Ohio State University | Water soluble polymers containing amino acid residues for dental restoratives |
| WO1995003558A1 (en) | 1993-07-19 | 1995-02-02 | Reflexite Corporation | Retroreflective structure |
| DE4406424A1 (de) | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
| US5837276A (en) | 1994-09-02 | 1998-11-17 | Delab | Apparatus for the delivery of elongate solid drug compositions |
| US6962579B2 (en) | 1995-03-23 | 2005-11-08 | Advanced Animal Technology Limited | Substance delivery device |
| DE69628344T2 (de) | 1995-03-23 | 2004-04-01 | Advanced Animal Technology Ltd. | Vorrichtung zur Verabreichung einer Substanz |
| DE19539361A1 (de) | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| AU2521797A (en) | 1996-04-12 | 1997-11-07 | Japan Atomic Energy Research Institute | Ph-sensitive polymers |
| ES2234139T3 (es) | 1997-08-11 | 2005-06-16 | Alza Corporation | Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica. |
| DE19850309A1 (de) | 1998-10-30 | 2000-05-04 | Lohmann Therapie Syst Lts | Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer |
| IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| JP5178982B2 (ja) | 2000-05-18 | 2013-04-10 | セリックス， インコーポレイテッド | 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化 |
| WO2001091553A1 (en) | 2000-05-26 | 2001-12-06 | Demegen, Inc. | Composite wafer for controlled drug delivery |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US8158143B2 (en) | 2000-07-14 | 2012-04-17 | Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh | Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect |
| US7803392B2 (en) | 2000-12-27 | 2010-09-28 | University Of Kentucky Research Foundation | pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules |
| US6627206B2 (en) | 2001-07-25 | 2003-09-30 | Greg A. Lloyd | Method and apparatus for treating obesity and for delivering time-released medicaments |
| US20040219186A1 (en) | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
| JP2005501097A (ja) | 2001-08-16 | 2005-01-13 | ザ ステイト オブ オレゴン アクティング バイ アンド スルー ザ ステイト ボード オブ ハイアー エデュケイション、 オン ビハーフ オブ オレゴン ステイト ユニバーシティー | 膨張可能な胃内滞留装置 |
| US20050165136A1 (en) | 2002-01-23 | 2005-07-28 | Uab Research Foundation | Glass-ionomer cements containing amino acids |
| US6960617B2 (en) | 2002-04-22 | 2005-11-01 | Purdue Research Foundation | Hydrogels having enhanced elasticity and mechanical strength properties |
| DE10224352A1 (de) | 2002-06-01 | 2003-12-11 | Mueller Schulte Detlef | Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie |
| GB0214013D0 (en) | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
| MY142179A (en) | 2002-07-25 | 2010-10-15 | Glaxo Group Ltd | Multicomponent pharmaceutical dosage form |
| CA2501345A1 (en) | 2002-10-11 | 2004-04-22 | Depomed Development, Ltd. | Gastro-retentive levodopa delivery form |
| WO2004073690A1 (en) | 2003-02-19 | 2004-09-02 | Mnemoscience Gmbh | Self-expanding device for the gastrointestinal or urogenital area |
| JP4497833B2 (ja) | 2003-04-21 | 2010-07-07 | 富士フイルム株式会社 | ポジ型平版印刷版原版 |
| US7662864B2 (en) | 2003-06-04 | 2010-02-16 | Rutgers, The State University Of New Jersey | Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent |
| US20070129784A1 (en) | 2003-06-13 | 2007-06-07 | Mnemoscience Gmbh | Stents |
| WO2004112755A1 (en) | 2003-06-18 | 2004-12-29 | John Michael Newton | Controlled release devices with lumens |
| US20090259236A2 (en) | 2003-07-28 | 2009-10-15 | Baronova, Inc. | Gastric retaining devices and methods |
| US8048169B2 (en) | 2003-07-28 | 2011-11-01 | Baronova, Inc. | Pyloric valve obstructing devices and methods |
| DE10350556A1 (de) | 2003-10-29 | 2005-06-02 | Clariant Gmbh | Wasserbasierende Pigmentpräparationen |
| US6825308B1 (en) | 2003-10-29 | 2004-11-30 | Council Of Scientific And Industrial Research | Copolymers and preparation thereof |
| WO2005056708A2 (en) | 2003-12-09 | 2005-06-23 | Spherics, Inc. | Bioadhesive polymers with catechol functionality |
| EP1703898A2 (en) | 2003-12-31 | 2006-09-27 | Alpharma, Inc. | Ziprasidone formulations |
| US20080089933A1 (en) | 2006-10-16 | 2008-04-17 | Amir Alon | Device and method for reducing calorie intake |
| TW200539903A (en) | 2004-03-12 | 2005-12-16 | Smithkline Beecham Plc | Pharmaceutical formulations |
| US7964196B2 (en) | 2004-05-25 | 2011-06-21 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| DE102004047076A1 (de) | 2004-09-28 | 2006-04-06 | Zimmer Ag | Verfahren zur Herstellung von Polyestern |
| IL166183A0 (en) | 2005-01-06 | 2006-01-15 | Yissum Res Dev Co | Novel diagnostic and imaging techniques of the gi tract |
| AU2006209239A1 (en) | 2005-01-27 | 2006-08-03 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrophilic biocompatible adhesive formulations and uses |
| JP5175553B2 (ja) | 2005-02-01 | 2013-04-03 | エミスフェアー・テクノロジーズ・インク | 胃内滞留および制御放出型送達系 |
| US7785291B2 (en) | 2005-03-01 | 2010-08-31 | Tulip Medical Ltd. | Bioerodible self-deployable intragastric implants |
| JP2006323082A (ja) | 2005-05-18 | 2006-11-30 | Canon Inc | 現像剤補給容器 |
| US8021384B2 (en) | 2005-07-26 | 2011-09-20 | Ram Weiss | Extending intrabody capsule |
| JP4981671B2 (ja) | 2005-08-05 | 2012-07-25 | 滋賀県 | ポリマーブレンドを含んでなる液中物質捕集材料 |
| US20070048383A1 (en) | 2005-08-25 | 2007-03-01 | Helmus Michael N | Self-assembled endovascular structures |
| EP1957052A2 (en) | 2005-10-25 | 2008-08-20 | Pharmascience Inc. | A gastric retention drug delivery system |
| US8187633B2 (en) | 2005-11-03 | 2012-05-29 | Sun Pharma Advanced Research Company Limited | Controlled release coated tablets having prolonged gastric retention |
| US7674396B2 (en) | 2005-11-08 | 2010-03-09 | Plensat Llc | Method and system for treatment of eating disorders |
| DK2997953T3 (en) | 2006-01-18 | 2019-04-15 | Intec Pharma Ltd | ADMINISTRATION ORAL ADMINISTRATION |
| WO2007093999A1 (en) | 2006-02-15 | 2007-08-23 | Intec Pharma Ltd. | A gastro-retentive system for the delivery of macromolecules |
| US20090246142A1 (en) | 2006-03-10 | 2009-10-01 | Massachusetts Institute Of Technology | Triggered Self-Assembly of Nanoparticles In Vivo |
| US7691151B2 (en) | 2006-03-31 | 2010-04-06 | Spiration, Inc. | Articulable Anchor |
| US20070264307A1 (en) | 2006-05-15 | 2007-11-15 | Medtronic Vascular, Inc. | Biodegradable Modified Caprolactone Polymers for Fabricating and Coating Medical Devices |
| EP1886665A1 (en) | 2006-08-01 | 2008-02-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Gastro retentive delivery system |
| KR20090065524A (ko) | 2006-09-04 | 2009-06-22 | 파나세아 바이오테크 리미티드 | 프로그래머블 부력전달기술 |
| US20080075766A1 (en) | 2006-09-25 | 2008-03-27 | Shun-Por Li | Multi-core dosage form having transparent outer coating |
| CA2673511A1 (en) | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| WO2008140651A2 (en) | 2007-03-13 | 2008-11-20 | Olson Arthur J | Self-assembled polyhedra |
| US20100297009A1 (en) | 2007-03-13 | 2010-11-25 | Technion Research & Development Foundation Ltd. | Self-assembled polyhedral multimeric chemical structures |
| US20080249156A1 (en) | 2007-04-09 | 2008-10-09 | Palepu Nageswara R | Combinations of statins and anti-obesity agent and glitazones |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| US8481076B2 (en) | 2007-05-25 | 2013-07-09 | Gorham Enterprises Llc | Bariatric magnetic apparatus and method of manufacturing thereof |
| US8038659B2 (en) | 2007-10-17 | 2011-10-18 | The Invention Science Fund I, Llc | Disintegrating digestive tract interaction system |
| US8637455B2 (en) | 2007-10-22 | 2014-01-28 | Affinergy, Llc | Compositions and methods for delivery of glycopeptide antibiotics to medical device surfaces |
| EP2262367A4 (en) | 2008-03-08 | 2011-04-20 | Theraquest Biosciences Inc | PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE |
| WO2009114648A1 (en) | 2008-03-11 | 2009-09-17 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| US20130273135A1 (en) | 2008-03-25 | 2013-10-17 | University Of Utah Research Foundation | Controlled Release Combination Biomaterials |
| DK2276473T3 (en) | 2008-04-18 | 2017-01-09 | Intec Pharma Ltd | GASTRORETENTIV drug TO carbidopa / levodopa |
| US9066877B2 (en) | 2008-04-28 | 2015-06-30 | Eat Little Inc. | Bezoar-forming units for weight control |
| US20100256342A1 (en) | 2008-08-12 | 2010-10-07 | Francis Raymond Salemme | Protein nodes for controlled nanoscale assembly |
| KR20110042366A (ko) | 2008-08-18 | 2011-04-26 | 팀 아카데미 오브 파마슈티컬 사이언스 | 위장체류 약물 전달 시스템, 제작 방법 및 그것들의 사용 |
| US20110268666A1 (en) | 2008-09-29 | 2011-11-03 | Yissum Research Development Company of the Research University of Jerusalem, Ltd. | Novel gastroretentive delivery system |
| AU2009303347B2 (en) | 2008-10-10 | 2013-10-24 | Reva Medical, Inc. | Expandable slide and lock stent |
| WO2010064139A2 (en) | 2008-12-04 | 2010-06-10 | Intec Pharma Ltd. | Zaleplon gastroretentive drug delivery system |
| AU2009330716A1 (en) | 2008-12-27 | 2011-08-18 | Chandra S. Duggirala | Devices for treating obesity and methods of using those devices |
| EP2401225B1 (en) | 2009-02-26 | 2014-10-22 | The Regents of The University of California | A supramolecular approach for preparation of size controllable nanoparticles |
| US8414559B2 (en) | 2009-05-07 | 2013-04-09 | Rainbow Medical Ltd. | Gastroretentive duodenal pill |
| DE102009028076A1 (de) | 2009-07-29 | 2011-02-03 | Evonik Röhm Gmbh | Beschichtungsmittel zum Tauchbeschichten von Kapselhälften |
| US20110052700A1 (en) | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride |
| WO2011032087A2 (en) | 2009-09-11 | 2011-03-17 | Replication Medical Inc. | Swellable polymeric device for dietary regulation |
| WO2011048494A2 (en) | 2009-10-19 | 2011-04-28 | Intec Pharma Ltd. | Novel gastroretentive dosage forms of poorly soluble drugs |
| US9421169B2 (en) | 2009-11-20 | 2016-08-23 | Covidien Lp | Oral dosage forms for delivery of therapeutic agents |
| CN101711752B (zh) | 2009-11-26 | 2011-09-21 | 中国科学院上海药物研究所 | 一种苯并异噁唑类衍生物的控释制剂及其制备方法 |
| WO2011139796A2 (en) | 2010-04-27 | 2011-11-10 | The Johns Hopkins University | Self-folding sub-centimeter structures |
| US20120009261A1 (en) | 2010-07-06 | 2012-01-12 | Grünenthal GmbH | Novel gastro-retentive dosage forms |
| EP3711750B1 (en) | 2010-08-05 | 2023-09-06 | TARIS Biomedical LLC | Implantable drug delivery devices for genitourinary sites |
| US20120165793A1 (en) | 2010-12-22 | 2012-06-28 | Ethicon Endo-Surgery, Inc. | Pill Catchers |
| US20120165794A1 (en) | 2010-12-22 | 2012-06-28 | Ethicon Endo-Surgery, Inc. | Pill Catchers |
| US20120165792A1 (en) | 2010-12-22 | 2012-06-28 | Ethicon Endo-Surgery, Inc. | Pill Catchers |
| RU2598057C2 (ru) | 2011-02-04 | 2016-09-20 | ТАРИС Биомедикал ЛЛК | Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью |
| EP2764557A4 (en) | 2011-09-26 | 2016-04-27 | Univ Northeastern | ADJUSTABLE EMBEDDED SENSORS |
| ES2603278T3 (es) | 2011-12-09 | 2017-02-24 | Purdue Pharma Lp | Formas farmacéuticas de dosificación que comprenden poli (epsilon-caprolactona) y óxido de polietileno |
| US8979887B2 (en) | 2012-02-24 | 2015-03-17 | Elwha Llc | Devices, systems, and methods to control stomach volume |
| AU2013290875A1 (en) | 2012-07-16 | 2015-02-05 | APET Holding B.V. | Gastro-retentive drug delivery system |
| US9307966B2 (en) | 2012-08-15 | 2016-04-12 | St. Jude Medical Puerto Rico Llc | Vascular closure device anchor |
| ES2623176T3 (es) | 2012-08-16 | 2017-07-10 | Teva Pharmaceutical Industries Ltd. | Composición farmacéutica de memantina |
| US10441760B2 (en) | 2013-03-01 | 2019-10-15 | The Johns Hopkins University | Self-actuating chemomechanical devices for delivery and extended release of therapeutic agents in the gastrointestinal tract |
| CN103654903A (zh) | 2013-11-27 | 2014-03-26 | 西安交通大学 | 一种用于人体消化道吻合的磁性可降解装置 |
| WO2015083171A1 (en) | 2013-12-05 | 2015-06-11 | Tulip Medical Ltd. | Retentive devices and systems for in-situ release of pharmaceutical active agents |
| US20170051099A1 (en) | 2014-04-29 | 2017-02-23 | The Brigham And Women's Hospital, Inc. | Polymeric materials for bio-applications |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US10485758B2 (en) | 2014-06-02 | 2019-11-26 | Clexio Biosciences Ltd. | Expandable gastroretentive dosage form |
| MX2016016406A (es) | 2014-06-11 | 2017-10-12 | Massachusetts Inst Technology | Estructuras de permanencia, y métodos relacionados. |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| WO2016178971A1 (en) | 2015-05-01 | 2016-11-10 | Massachusetts Institute Of Technology | Triggerable shape memory induction devices |
| AU2016342374B2 (en) | 2015-10-23 | 2022-08-04 | Nortiva Bio, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
| JP2018536007A (ja) | 2015-12-01 | 2018-12-06 | クレキシオ バイオサイエンシーズ エルティーディー． | 胃保持性装置 |
| JP2018537201A (ja) | 2015-12-02 | 2018-12-20 | クレキシオ バイオサイエンシーズ エルティーディー． | 胃保持型投与形態を調整する装置および方法 |
| KR102796240B1 (ko) | 2015-12-08 | 2025-04-16 | 린드라 테라퓨틱스 인코퍼레이티드 | 위 체류 시스템을 위한 기하 구성형태 |
| US12109305B2 (en) | 2016-05-27 | 2024-10-08 | Lyndra Therapeutics, Inc. | Materials architecture for gastric residence systems |
| US20200230244A1 (en) | 2016-11-09 | 2020-07-23 | Massachusetts Institute Of Technology | Triggerable hydrogel compositions and related methods |
| ES2966736T3 (es) | 2016-12-02 | 2024-04-24 | Clexio Biosciences Ltd | Sistema de residencia gástrica |
| TWI811221B (zh) | 2017-06-09 | 2023-08-11 | 美商萊恩卓治療公司 | 具有釋放速率調節膜之胃的滯留系統 |
| JP7288435B2 (ja) | 2017-09-20 | 2023-06-07 | リンドラ セラピューティクス， インコーポレイティド | 胃内滞留システムのカプセル封入 |
| WO2019111132A1 (en) | 2017-12-04 | 2019-06-13 | Clexio Biosciences Ltd. | Long acting gastric residence system |
| WO2019232291A1 (en) | 2018-05-31 | 2019-12-05 | Massachusetts Institute Of Technology | Drug delivery articles for gram-level dosing |
| WO2020102648A1 (en) | 2018-11-15 | 2020-05-22 | Massachusetts Institute Of Technology | Millineedle systems for esophageal drug delivery |
-
2017
- 2017-09-29 EP EP17857587.4A patent/EP3518902A4/en active Pending
- 2017-09-29 CN CN202410745376.9A patent/CN118766834A/zh active Pending
- 2017-09-29 CA CA3038557A patent/CA3038557A1/en active Pending
- 2017-09-29 JP JP2019516937A patent/JP2019532947A/ja not_active Withdrawn
- 2017-09-29 WO PCT/US2017/054608 patent/WO2018064630A1/en not_active Ceased
- 2017-09-29 AU AU2017336154A patent/AU2017336154B2/en active Active
- 2017-09-29 US US16/333,582 patent/US11576866B2/en active Active
- 2017-09-29 CN CN201780074281.7A patent/CN110022861B/zh active Active
-
2022
- 2022-12-20 JP JP2022203459A patent/JP7565999B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023087016A5 (enExample) | ||
| JP2019532947A5 (enExample) | ||
| JP5755878B2 (ja) | リファキシミンの薬剤組成物 | |
| US12017989B2 (en) | Controlled release pharmaceutical formulations | |
| ES2389358T3 (es) | Composiciones farmacéuticas de rifaximina | |
| JP2011500552A (ja) | 胃腸障害を処置するための医薬用組み合わせおよび組成物 | |
| JP2010532746A (ja) | 放出調節医薬組成物およびその製造方法 | |
| EP3836866A1 (en) | Systems for enteric delivery of therapeutic agents | |
| KR101062687B1 (ko) | 헤파린 또는 그의 유도체를 경구 투여하기 위한 약학적 조성물 | |
| CN109310642A (zh) | 美沙拉嗪的口服药物组合物 | |
| US20040033262A1 (en) | Sustained release pharmaceutical composition of a cephalosporin antibiotic | |
| US7037523B2 (en) | Controlled release compositions for macrolide antimicrobial agents | |
| US9119793B1 (en) | Gastroretentive dosage forms for doxycycline | |
| KR100920856B1 (ko) | 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법 | |
| CA2706730C (en) | Single layered controlled release therapeutic system | |
| US20120027855A1 (en) | Pharmaceutical compositions for gastrointestinal drug delivery | |
| US9561241B1 (en) | Gastroretentive dosage forms for minocycline | |
| EP4225269A1 (en) | Gastro retentive dosage forms comprising deutetrabenazine | |
| CN114177137A (zh) | 一种基于免疫激活的胍基化纳米药物及其制备和应用 | |
| Chandra et al. | In SITU Gelling System as a Vaccine Carrier |